A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2

British Journal of Haematology

Volumn 113, Issue 2, 2001, Pages 455-460

  Schultze, J L ^a,b   Anderson, K C ^a,b   Gilleece, M H ^a,b   Gribben, J G ^a,b   Nadler, L M ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adoptive cell transfer; CD40 antigen; Haematological malignancies; Plasmacytic leukaemia; T cells

Indexed keywords

CD40 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GAMMA INTERFERON; GLYCOPROTEIN GP 39; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN IDIOTYPE; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELPHALAN; RECOMBINANT INTERLEUKIN 4; VACCINE; VINCRISTINE;

ADOPTIVE TRANSFER; ADULT; ARTICLE; B LYMPHOCYTE; CASE REPORT; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LEUKAPHERESIS; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TREATMENT FAILURE; VACCINATION;

ADOPTIVE TRANSFER; ANTIGENS, CD40; B-LYMPHOCYTES; FEASIBILITY STUDIES; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; LEUKEMIA, PLASMACYTIC; LYMPHOCYTE ACTIVATION; MIDDLE AGED; PILOT PROJECTS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 0034995643     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02760.x     Document Type: Article

References (19)

1. Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells
2. Therapy with cultured T cells: Principles revisited
3. Recent advances in the treatment of multiple myeloma
4. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes
5. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells
6. Adoptive immunotherapy with donor lymphocyte transfusions
7. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumours
8. Pathways of T-cell regeneration in mice and humans: Implications for bone marrow transplantation and immunotherapy
9. Proliferation of B cell malignancies in all stages of differentiation upon stimulation in the "CD40 system"
10. B7-2-positive myeloma: Incidence, clinical characteristics, prognostic significance, and implications for tumour immunotherapy
11. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal
12. Follicular lymphomas can be induced to present alloantigen efficiently: A conceptual model to improve their tumour immunogenicity
13. Autologous tumour infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro
14. CD40 activated human B cells: An alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy
15. Tumour-specific adoptive T-cell therapy for CD40+ B-cell malignancies
16. Interleukin-2 toxicity
17. The telomerase catalytic subunit is a widely expressed tumour-associated antigen recognized by cytotoxic T lymphocytes
18. Current approaches to the management of non-Hodgkin's lymphoma
19. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor